Developer of T-cell receptor-based therapeutics for cancer and autoimmune diseases. The company has proprietary technologies combining genome editing, functional high-throughput screening, deep sequencing, and machine learning to address T-cell receptor therapies for the treatment of cancer. Also, it is expanding its pipeline to treat autoimmune diseases.
← All startups
Engimmune Therapeutics
SeedDeveloper of T-cell receptor-based therapeutics for cancer and autoimmune diseases. The company has proprietary technologies combining genome editing, functional high-throughput screening, deep sequencing, and machine learning to address T-cell receptor therapies for the treatment of cancer. Also, it is expanding its pipeline to treat autoimmune diseases.
About
Institutional investors
Pureos BioventuresNovo HoldingsBaseLaunchNovoseeds
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.
Similar startups
Raising like Engimmune Therapeutics?
Analyze your pitch deck before your next raise.
Analyze My Deck →